In a randomized study comparing direct intra-lymph-nodal, intravenous and intradermal administration of DC vaccines in patients with metastatic melanomas [29], the intra-lymph-nodal route was well-tolerated for up to 5 × 107 DCs/injection, and induced significantly higher levels of specific CD8+ T cells based on cytokine secretion, when compared with other routes. This evidence concerns the gene CD8A and metastatic melanoma.